Study provides new look at why rare cancer often evades treatments
Por um escritor misterioso
Descrição
Researchers at Boston Medical Center and Dana-Farber Cancer Institute have conducted one of the first-ever analyses of neuroendocrine tumors (NETs) at single-cell resolution, unlocking new insights into this rare and often hard-to-treat cancer. The findings represent a tremendous leap forward in understanding why these tumors are largely resistant to immunotherapy and provide key insights that could lead to future treatments.
Outsmart Your Cancer: Alternative by Pierce, Tanya Harter
The cancer equation: Mathematically modelling the cure, The Independent
Hope for breast cancer patients, but with a cruel caveat — Harvard Gazette
Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications
What is tumor-infiltrating lymphocyte (TIL) therapy?
Using genomics to guide personalized cancer treatment
How Chaos in Chromosomes Helps Drive Cancer Spread, TS Digest
Organoids study finds potential new treatment for pulmonary neuroendocrine tumors
Dana-Farber Cancer Institute on LinkedIn: Study provides new look at why rare cancer often evades treatments
Study Provides New Look at Why Rare Cancer Often Evades Treatments - Cancer Health
Study Provides New Look at Why Rare Cancer Often Evades Treatments
What is microsatellite instability?
How cancer doesn't happen - Part 2
de
por adulto (o preço varia de acordo com o tamanho do grupo)